Stockscreener 앱 받기
101.55
0.54%
0.55
시장 영업 전:
102.05
0.50
+0.49%
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Canada
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - lincolnjournal.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan
CenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLC - MarketBeat
Mirum (MIRM) President and COO exercises options, boosts direct share holdings - Stock Titan
5,000-share resale notice for MIRM (NASDAQ: MIRM) affiliate; prior sale noted - Stock Titan
Mirum Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates Significantly, Shares Edge HigherEarnings Quality Analysis - newsline.com
Mirum Pharmaceuticals (MIRM) Edges Higher as Bulls Test Resistance Near $98BPI Bear Confirmed - newsline.com
Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08D - TradingView
EBITDA of Mirum Pharmaceuticals, Inc. – XETR:08D - TradingView
Discipline and Rules-Based Execution in MIRM Response - Stock Traders Daily
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report? - Yahoo Finance
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth - Investing.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - BioSpace
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com Canada
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress - Insider Monkey
Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing - Moomoo
HC Wainwright & Co. Maintains Mirum Pharmaceuticals (MIRM) Buy Recommendation - MSN
Mirum director Saira Ramasastry sells $397,700 of company stock By Investing.com - Investing.com South Africa
Insider Sell: Saira Ramasastry Sells 3,977 Shares of Mirum Pharm - GuruFocus
Mirum CEO Peetz sells $2.88m in stock after exercising options - Investing.com Nigeria
Mirum director Saira Ramasastry sells $397,700 of company stock - Investing.com
Mirum CEO Peetz sells $2.88m in stock after exercising options By Investing.com - Investing.com India
Mirum (MIRM) director converts 3,977 restricted stock units into common shares - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Mirum Pharmaceuticals (MIRM) director converts 3,977 RSUs into 9,680-share holding - Stock Titan
Mirum Pharmaceuticals (MIRM) director sells 3,977 shares under 10b5-1 plan - Stock Titan
MIRM Initiated Coverage by Citigroup -- Rating Set to Buy - GuruFocus
Insider sale and option exercise — MIRM: 40,985 shares sold, 30,000 planned - Stock Titan
3,977-share planned restricted-stock sale by MIRM (NASDAQ: MIRM) - Stock Titan
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline - Investing.com
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Pushes Higher, Approaches Key ResistanceBullish Percent Index - newsline.com
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 - Weekly Voice
1.27%
1.43%
자본화:
|
볼륨(24시간):